Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $251 | $55 | $58 | $57 |
| Short-Term Investments | $262 | $205 | $228 | $248 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $10 | $6 | $5 |
| Total Curr. Assets | $521 | $270 | $291 | $310 |
| Property Plant & Equip (Net) | $14 | $14 | $11 | $5 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $0 | $0 |
| Total NC Assets | $15 | $15 | $11 | $5 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $535 | $285 | $302 | $315 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $2 | $2 |
| Short-Term Debt | $2 | $2 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $9 | $7 | $6 | $6 |
| Total Curr. Liab. | $14 | $12 | $9 | $9 |
| LT Debt | $9 | $10 | $7 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $9 | $10 | $7 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $12 | $8 | $1 |
| Total Liabilities | $24 | $22 | $16 | $10 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$201 | -$175 | -$148 | -$124 |
| AOCI | $0 | -$0 | -$0 | -$1 |
| Other Equity | $713 | $438 | $434 | $430 |
| Total Equity | $512 | $264 | $286 | $305 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $535 | $285 | $302 | $315 |
| Net Debt | -$239 | -$43 | -$50 | -$55 |